Syngeneic leukemia models using lentiviral transgenics

Nurit Keinan, Ye’ela Scharff, Oron Goldstein, Michael Chamo, Stefan Ilic, Roi Gazit*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies.

Original languageEnglish
Article number193
JournalCell Death and Disease
Issue number2
StatePublished - Feb 2021
Externally publishedYes


Dive into the research topics of 'Syngeneic leukemia models using lentiviral transgenics'. Together they form a unique fingerprint.

Cite this